Organizing Committee


Melissa Carpenter, PhD
ElevateBio, USA

Derek Hei, PhD
Vertex Pharmaceuticals, USA

Malin Parmar, PhD
Lund University, Sweden

IS Boston Web Banner

Call for Abstracts

Abstract submission for the 2022 Boston International Symposium is open, 4 October - 24 November 2021. Abstracts submissions have closed.

Abstract submissions will be considered for both oral and poster presentations, in the topics:

  • Preclinical strategies
  • Selecting your cell line: Derivation and characterization
  • Characterization of the final cell product
  • New technologies for cell therapy
  • Immunology for cell therapies

Only meeting attendees registered as in-person may submit an abstract. In-person registrants will receive an email with the link to the abstract submission site. Oral and poster presentations will only be presented in person.

There is a non-refundable $35.00 USD abstract submission fee for each abstract submitted.

Presentation notifications will be sent by 15 December 2021 Extended to 22 December 2021.

Please contact abstracts@isscr.org with any questions. 


Abstract Submission Requirements

All abstract submissions are screened by the Program Committee to ensure that they meet these standards. Failure to comply with these terms constitutes grounds for abstract rejection.

Substantial experimental, calculated, or theoretical results must be included.
Abstract must adhere to the principles in the ISSCR Guidelines for Stem Cell Research and Clinical Translation.
Results are the work of the listed author(s). 
Abstract must adhere to Abstract Submission Agreement


Abstract Submission Overview

To ensure a smooth submission experience, submitters should review these items carefully and have the in advance to have the right data on hand. Average submission can take up to 20 minutes.

  • Abstract Title: Abstract Titles are limited to 175 characters, including spaces. Titles should be in ALL CAPS. 
  • Submission Type: You can submit your abstract for consideration as an oral and/or a poster presentation. Abstracts not selected for an oral presentation will automatically be considered for a poster presentation.
    • Oral: A limited number of abstracts will be selected for oral presentations. Abstracts not chosen for an oral presentation will automatically be considered for a poster presentation.
    • Poster: Posters will be displayed for the entire meeting and presented during a poster session on Monday, 28 February 2022.
  • Presenter: The head author should be listed as the presenting author for the abstract. Each abstract may indicate only one presenting author.
  • Co-author(s): Each abstract can include a maximum of 24 co-authors.
    • When adding co-authors for this submission be certain department and institution names are entered identically for all authors who share them on this abstract.
    • Review your entries for correct spelling and capitalization (capitalize only the first letter of each name) to ensure your author block is printed correctly in meeting materials.
  • Abstract Text: Abstracts are limited to 2,000 letters, not including spaces. Abstracts must be formatted as one paragraph; those not in compliance will be edited to conform to this format. Abstract text should not include section titles (such as Methods, Results, Conclusions), tables, graphs, charts, diagrams, authors, or references or acknowledge funding sources. 
  • Session Topics: Choose the most appropriate session topic that fits your research. Topics will be used for oral consideration and for poster hall organization.
    • Preclinical strategies
    • Selecting your cell line: Derivation and characterization
    • Characterization of the final cell product
    • New technologies for cell therapy
    • Immunology for cell therapies
  • Keywords: Indicate three keywords that highlight the main topics of your abstract. 
  • Funding Source: You may choose to include funding sources or grants that your work. This is limited to 500 characters, not including spaces.
  • Experimental treatments to human subjectsYou must indicate if the research described involves experimental stem cell-based treatments to human subjects, and if so, share the institutional review board and/or national or local regulatory agency that reviewed it, the clinical trial reference numbers and other identifying information (i.e. name of the granting authority, and URL, etc.)

Submission Fee

There is a non-refundable $35.00 USD abstract submission fee for each abstract submitted. Payment must be made by credit card (MasterCard, Visa, American Express and Discover accepted).


Review & Notification of Result

Submitted abstracts will be reviewed by the committee. Acceptance/rejection of abstracts will be notified to the submitters via email. Presentation notifications will be sent by 15 December 2021 Extended to 22 December 2021.